News Digest /
Income Statements /
Teladoc Reports Q2 2025 Results: Revenue Declines but Loss Narrows Significantly
Teladoc Reports Q2 2025 Results: Revenue Declines but Loss Narrows Significantly
StockInvest.us
01:01pm, Wednesday, Jul 30, 2025
Illustration by StockInvest.us
Teladoc Health, Inc. (NYSE: TDOC)
Teladoc Health, Inc. has recently reported its financial results for the second quarter of 2025. Here are the key points:
- Revenue: Total revenue for Q2 2025 was $631.9 million, a decrease of 2% compared to $642.4 million in Q2 2024. Year-to-date revenue as of June 30, 2025, was $1.261 billion, down from $1.289 billion in the same period last year.
- Cost Management: Total costs and expenses dropped significantly to $686.3 million from $1.484 billion in Q2 2024, primarily due to the absence of a goodwill impairment charge that was present in the previous year.
- Net Loss: The net loss narrowed sharply to $32.7 million, or $0.19 per share, compared to a loss of $837.7 million, or $4.92 per share, in Q2 2024.
- Adjusted EBITDA: Adjusted EBITDA was $69.3 million, compared to $89.5 million a year ago, reflecting a decrease of 23%.
Positive Aspects:
- Elimination of larger impairment charges in 2025 contributes to reduced overall costs.
- Revenue from the Integrated Care segment increased by 4% to $391.5 million, supported by acquisitions like Catapult Health.
- Cash flow from operating activities increased to $107.4 million, up from $97.6 million in the prior year.
Negative Aspects:
- Overall revenue decline is mainly attributed to decreased performance in the BetterHelp segment, which saw a 9% drop in revenue.
- Average monthly revenue per U.S. Integrated Care member fell to $1.27, down from $1.36 year-over-year.
- Continued legal challenges and class action lawsuits may pose ongoing risks to business operations and financial performance.
Balance Sheet Highlights:
- As of June 30, 2025, cash and cash equivalents stood at $679.6 million, down from $1.3 billion at the end of 2024.
- Total liabilities decreased to $1.472 billion, down from $2.025 billion at the end of the previous fiscal year.
- Equity shows an accumulated deficit of $16.4 billion as of June 30, 2025.
In summary, while Teladoc Health has made strides in reducing its loss and managing costs, it faces challenges in revenue generation, particularly within its BetterHelp segment. Continued legal pressures may also affect future performance.
About The Author
StockInvest.us
StockInvest.us is a stock market research tool that provides daily stock signals and technical analysis for over 25 000 tickers on 38 exchanges. The company was founded in 2016 in Vilnius, Lithuania.
Read Next in Income Statements
Trusted Broker
Start Your Journey With:
0% Commission Stock Trading
Follow Other Investors Strategy
Wide variety: Crypto, stocks, ETFs
Sign In